Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI

Core Insights - Absci Corporation has announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop novel therapeutics using generative AI for up to six programs [1] - The collaboration aims to leverage Absci's Integrated Drug Creation™ platform alongside MSK's expertise in oncology to advance cancer treatment [1] - Absci has established multiple partnerships with global pharmaceutical leaders and research institutes, enhancing its drug development capabilities [1] Company Overview - Absci is a generative AI drug creation company that integrates AI with scalable wet lab technologies to accelerate the development of biologics [2] - The Integrated Drug Creation™ platform allows Absci to optimize multiple drug characteristics simultaneously, significantly increasing the probability of success in drug development [2] - The company can screen billions of cells weekly, enabling rapid progression from AI-designed antibodies to wet lab-validated candidates in as little as six weeks [2] Collaboration Details - The partnership with MSK is part of Absci's broader strategy to collaborate with leading research institutions and pharmaceutical companies to develop innovative therapies [1] - Absci's existing collaborations include partnerships with AstraZeneca, Almirall, Merck, and NVIDIA, indicating a strong network within the pharmaceutical industry [1] - The collaboration with MSK is expected to enhance cancer research and the development of new therapies for patients [1]